Quotient Sciences contributes to Pharma Manufacturing "2022 Pharma Predictions" Article
Matthew Paterson, Vice President of Corporate Strategy, comments on growing demand for integrated drug substance and drug product services.
We're seeing a greater desire to move deeper in development toward proof-of-concept. Biotechs want to have confidence in drug substance and drug product suitability for development, mitigating risks for commercialization and in turn driving up their valuations. This means we’re observing strong demand for integrated drug substance and drug product services — to help biotech’s accelerate development programs, anticipate downstream challenges, and improve the likelihood of clinical success.